Telix   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Melbourne Australia (2017)
Status: No NME R&D (2017)

Organization Overview

First Clinical Trial
2019
NCT03762759
First Marketed Drug
2021
68ga-psma
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

TELIX | Telix International Pty Ltd | Telix Pharmaceutical